# A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult

Source: https://onco.cc/trials/nct06669247/  
OnCo record `nct06669247` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Linvoseltamab in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting.

## Summary

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06669247 by Regeneron Pharmaceuticals, with 186 participants planned, started 2024-12-11 and due to reach its primary completion in 2033-11-11. Interventions recorded: Linvoseltamab, REGN7945+Linvoseltamab. Conditions listed: Relapsed/Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06669247
- Phase: 1/2
- Setting: A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 186

## Sources

- ClinicalTrials.gov NCT06669247: https://clinicaltrials.gov/study/NCT06669247

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Linvoseltamab](https://onco.cc/drugs/linvoseltamab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct06669247.json